论文部分内容阅读
2000年全世界新上市的药物数量与1999年持平,新药物及仿制药物上市的比例仍保持较高的增长。在30个新药物中,有15个在美国首次上市。在这30个新药物中包括4个疫苗类产品,在其他26个新药物中,阿斯利康公司的新一代质子泵抑制剂Nexium影响最大。目前全球质子泵抑制剂的市场竞争已趋白热化,而年销售额达60亿美元的络赛克抑制剂的专利保护即将期满,因此,Nexium就成了阿斯利康公司再次辉煌的法宝。研究表明,Nexium具有独特的药理特性,比其他PPI类药物(包括络赛克)更能有效加强对胃酸的控制。在新上市的生物类药品中,Genentech公司在溶解血栓药
The number of newly marketed drugs in the world in 2000 remained unchanged from 1999, and the proportion of new drugs and generic drugs listed on the market continued to grow at a high rate. Of the 30 new drugs, 15 are first listed in the United States. Among the 30 new drugs included four vaccine products, AstraZeneca’s new generation of proton pump inhibitor Nexium was the most influential of the other 26 new drugs. At present, the global proton pump inhibitor market competition has intensified, and the annual sales of 6 billion U.S. dollars of blocking the patent protection is about to expire, so Nexium has become AstraZeneca company once again a magic weapon. Studies have shown that Nexium has unique pharmacological properties that enhance gastric acid control more effectively than other PPIs, including lutecins. Among the new biopharmaceuticals listed, Genentech is thrombolytic